Stem-Cell–Derived Islet Research and Diabetes in Japan: Evidence, Risks and Regulatory Status
Japan Medical is an independent health-information publisher. It is not a hospital, clinic, laboratory, healthcare provider, referral service, or treatment coordinator. This page mainly concerns islet-cell research relevant to selected people with type 1 diabetes, and its findings should not be extended to everyone with diabetes. Japan Medical explains public evidence and regulatory sources only. It does not provide medical services, treatment advice or eligibility judgements.
Summarized from public sources
Key Takeaways
Population
Most diabetes cases worldwide are type 2, but the human islet-replacement evidence discussed on this page primarily concerns selected people with type 1 diabetes.[3][8]
Categories
Donor pancreatic islets, stem-cell-derived islets, mesenchymal stromal cells and exosomes are different interventions.[5]
Maturity
Early human results do not establish routine effectiveness, long-term safety or suitability for an individual.[8]
Diabetes Context in Numbers
In 2022, an estimated 830 million people worldwide were living with diabetes, representing about 14% of adults. More than 95% of people with diabetes have type 2 diabetes.[3]
Estimated worldwide in 2022[3]
Approximate share of adults living with diabetes in 2022[3]
Proportion of diabetes that is type 2[3]
These figures describe diabetes as a whole, not any study population
These global figures describe diabetes as a whole. They should not be presented as the potential population for an islet-cell intervention.
Published studies define narrow study populations
Which Type of Diabetes Does the Evidence Address?
- Type 2 diabetes
Represents more than 95% of diabetes globally.[3] Evidence from selected type 1 diabetes islet studies cannot be directly transferred to routine type 2 diabetes care.
- Gestational diabetes
Outside the scope of this page. Nothing here should be read as applying to pregnancy.
Intervention Map
These categories are not synonyms. The FDA warns that online information about stem-cell and exosome products is often misleading.[5]
Deceased-Donor Pancreatic Islets
Islets recovered from a deceased donor’s pancreas and infused into the liver. Evidence includes long-standing transplant programs and one US-approved product for a narrow group. The cited programs involve immunosuppression.[6] Results do not transfer to laboratory-grown cells.
Donor tissueStem-Cell–Derived Islets
Fully differentiated islet cells manufactured from pluripotent stem cells. Current human evidence consists of early, small studies in selected type 1 diabetes populations, with immunosuppression for every participant.[8] Approval status of donor tissue does not cover these products.
Manufactured cellsMesenchymal Stromal Cells
Stromal cells obtained from fat, bone marrow or other tissue. Research explores immune and inflammation pathways rather than direct islet replacement, so endpoints and populations differ from islet studies. Findings cannot substitute for islet-replacement evidence.[5]
Different questionExosome Products
Cell-free vesicle preparations. The FDA has warned consumers about unapproved exosome products and misleading claims.[5] Being cell-free does not make them equivalent to, or safer than, any cell therapy, and evidence is not interchangeable.
Cell-freeThe Evidence Ladder
Each rung answers a different question. Health benefit and safety claims should rest on reliable scientific evidence matched to the specific claim, and patient experiences cannot substitute for scientific studies.[7]
Rung 1Mechanism hypothesis
Can show: a plausible biological rationale. Cannot show: that patients benefit. Biological plausibility is not clinical benefit.
Rung 2Cell-culture evidence
Can show: behavior of cells under controlled laboratory conditions. Cannot show: effects in a human body.
Rung 3Animal evidence
Can show: whether a concept survives a living system. Cannot show: patient outcomes, because animal findings do not establish human benefit.
Rung 4Early human safety study
Can show: short-term tolerability in a small, selected group. Cannot show: effectiveness, rare risks or long-term outcomes.
Rung 5Controlled or confirmatory human study
Can show: whether measured outcomes differ meaningfully in a defined population. Cannot show: benefit beyond that population, dose, route and follow-up period.
Rung 6Regulatory review
Can show: that an authority evaluated a specific product for a specific indication. Cannot show: anything about other products, clinics or countries. Publication alone does not guarantee study quality.
Rung 7Long-term and post-market evidence
Can show: durability and less frequent harms over time. Cannot show: certainty for interventions that have not yet accumulated it. Evidence must match the exact intervention, dose, route, population and outcome.
Donor-Islet Therapy as a Jurisdiction-Specific Reference Point
In 2023, the US FDA approved Lantidra, a deceased-donor pancreatic islet cellular therapy, for a narrow group of adults with type 1 diabetes who continued to experience severe hypoglycemia despite intensive diabetes management and education.[4]
Results varied widely between participants, including a group with no insulin-free period.[4]
This US approval concerns deceased-donor islets. It is not approval of stem-cell-derived islets, mesenchymal stromal cells, exosomes, or services offered in Japan.
How to Read an Early Human Study
A 2025 study of stem-cell-derived, fully differentiated islets in type 1 diabetes illustrates why results and limitations must be read together. The analyses were interim and not prespecified, the study was small and short-term, and it was funded by Vertex Pharmaceuticals.[8]
Results reported
Limitations reported
- All participants received immunosuppressive therapy. Neutropenia was the most common serious adverse event, in 3 participants.[8]
- Two deaths occurred: one caused by cryptococcal meningitis, and one by severe dementia with agitation from progression of preexisting neurocognitive impairment.[8]
- A study of this size cannot determine rare or long-term risks.
Current Trial-Registry Status
A registry record documents a study and its planned methods. It does not by itself establish effectiveness, approval or routine availability.[9]
As of June 30, 2026[9]
As of June 30, 2026[9]
As of June 30, 2026[9]
June 30, 2027, as of June 30, 2026[9]
June 30, 2030, as of June 30, 2026[9]
Registry record last posted update[9]
Record: ClinicalTrials.gov NCT04786262. Dates and status can change; check the live record before citing.[9]
What the Outcomes Mean
Insulin independence is a study outcome, not a synonym for cure. A one-year result does not establish permanent benefit, glucose outcomes do not by themselves establish long-term safety, and continuing immunosuppression remains an important trade-off in the cited studies.[8]
C-peptide
A substance released when the body makes insulin. Detectable C-peptide after infusion was used to indicate engraftment and islet function in the cited study.[8]
HbA1c
A blood measure reflecting average glucose over roughly three months. It is a standard trial endpoint but does not capture daily glucose swings on its own.
Severe hypoglycemic event
Low blood glucose serious enough to require help from another person. Avoiding these events was a primary goal in the cited islet studies.[8]
Time in range
The share of time glucose stays within a target band, measured by continuous monitoring. It complements HbA1c by showing daily variation.
Insulin independence
A period in which a participant does not require injected insulin. It is measured over defined windows and can end; it is not the same as a cure.
Engraftment
Transplanted cells surviving and functioning in the recipient. Engraftment at one year does not guarantee function years later.
Adverse event
Any unfavorable medical occurrence during a study, whether or not it is caused by the intervention.
Serious adverse event
An adverse event that is life-threatening, requires hospitalization, causes lasting disability or death. Frequency and attribution both matter when reading a study.
Safety and Trade-offs
The cited islet programs combine a procedure, transplanted cells and continuing medication. Each layer carries its own risks.[6]
Procedure-Related
Bleeding, blood clots, portal-vein or infusion complications, and pain have been reported with islet infusion procedures.[6]
Infusion layerImmunosuppression-Related
Infection, blood-cell abnormalities, kidney effects, malignancy risk, and gastrointestinal and metabolic effects are recognized concerns with the medication regimens used after transplantation.[6]
Medication layerIntervention-Related or Uncertain
Graft failure, loss of function, immune rejection and uncertain long-term durability remain open questions, and small studies cannot reliably estimate rare or delayed adverse events.[8]
Open questionsJapan Regulatory Context
Three separate pathways are often confused. None of them should be described with phrases such as “Japan approved” or “officially authorized” unless a specific product record says so.
Clinical Research or Trial Registration
A registry entry records a study protocol and its status. It documents that research exists; it does not mean the research succeeded.[9]
Regenerative-Medicine Provision Plan
Japan’s provision-plan system involves review, submission, reporting and patient-information procedures for certain regenerative-medicine activities. Submission of a plan is not product marketing approval or proof of efficacy.[10]
PMD Act Marketing Approval
Commercialization of regenerative medical products follows the PMDA product-review pathway under the PMD Act. Any approval claim must be checked against the specific product, approval date and indication.[14]
How to Verify a Japan-Based Claim
Japan publishes provision-plan records and PMDA review information online.[11][15] Japan Medical does not list or recommend specific hospitals, clinics or addresses; names appearing in official records are record content, not a recommendation or partnership.
Identify what is offered
- Obtain the exact intervention or product name.
- Identify whether it is a marketed product, a registered clinical study, or a procedure under a submitted provision plan.
- Check the exact medical institution named in the official record.
- Check the provision-plan number and committee.[11]
- Read the patient information and consent document when available.
Check the regulatory record
- Search the PMDA approved-product and review-report pages.[15]
- Confirm that the approved indication matches diabetes and the exact intervention.
- Check whether approval is full, conditional, time-limited, expired, rejected or under review.
- Verify the date of the record.
- Do not treat a clinic’s own page as proof of regulatory status.
Marketing Red Flags
Japan’s health ministry warns against false, exaggerated and comparative advertising, treatment testimonials and potentially misleading before-and-after photographs.[12] Expressions such as “most advanced” or “best” can constitute exaggerated or comparative claims, and subjective experiences and ranking-style content can mislead.[13] Japan Medical applies these rules as editorial quality standards without claiming that every medical-advertising rule legally applies to this page.
Outcome Promises
Cure, reverse diabetes, permanent recovery, restore the pancreas, eliminate insulin, guaranteed, proven treatment, clinically proven based on one ingredient or a single study.
Superlatives
Breakthrough, revolutionary, world-leading, most advanced, cutting-edge treatment, best clinic, highest success rate, or a percentage without denominator, timeframe and outcome definition.
Social Proof
Completely safe, no side effects, painless, patient success stories, testimonials, before-and-after images, hospital rankings, partner-hospital logos, doctor endorsements, awards without verification.
Pressure Tactics
Limited availability, limited slots, countdown timers, book now, free consultation, check your eligibility, personalized treatment plan.
About Japan Medical and Editorial Method
Japan Medical is an independent health-information publisher. Japan Medical does not operate a hospital, clinic or laboratory and does not diagnose conditions, recommend treatments, assess eligibility, arrange care or review medical records.
Editorial responsibility: Japan Medical. Clinical review: not conducted. Evidence hierarchy: government agencies, regulators, public-health bodies, official trial registries and peer-reviewed research. Commercial clinic pages are not used as evidence of effectiveness or safety. Sponsor-funded studies may be included only when funding, design and limitations are disclosed. Individual testimonials are not used as evidence. Regulatory claims are checked against the relevant jurisdiction. Explaining who created content, how and why supports reader trust.[1][2]
Numbered sources below
Numbered sources. [1] Google — People-First Content · [2] Google — Article Structured Data · [3] WHO — Diabetes · [4] US FDA — Lantidra Approval · [5] US FDA — Consumer Alert · [6] NIDDK — Islet Transplantation · [7] US FTC — Health Products Compliance · [8] PubMed — Stem Cell–Derived Islets Study
[9] ClinicalTrials.gov — NCT04786262 · [10] Japan MHLW — Provision Plans · [11] Japan MHLW — Published Plan Database · [12] Japan MHLW — Medical Advertising Regulation · [13] Japan MHLW — Advertising Q&A · [14] PMDA — Regenerative Medical Products · [15] PMDA — Review Reports
Frequently Asked Questions
Which type of diabetes is the research on this page mainly about?
The human islet-replacement evidence discussed here mainly concerns selected adults with type 1 diabetes, particularly people who continue to experience severe hypoglycemia or impaired hypoglycemia awareness despite intensive management. Published donor-islet and stem-cell-derived islet studies enrolled that kind of population.[8] These results should not be read as evidence for routine type 2 diabetes care, which accounts for more than 95% of diabetes worldwide.[3]
Does insulin independence mean that diabetes has been cured?
No. Insulin independence is a study outcome measured over a defined period. In the cited studies it coexisted with continuing immunosuppressive therapy, and long-term durability beyond the follow-up period is not yet established.[8] A one-year or five-year result does not show permanent benefit, and glucose outcomes do not by themselves establish long-term safety.[4]
Why is immunosuppressive therapy used in the cited studies?
The transplanted cells come from donors or from allogeneic cell lines, so the recipient immune system would otherwise attack them. The 2025 stem-cell-derived islet study used a glucocorticoid-free immunosuppressive regimen for every participant.[8] Immunosuppression carries its own risks, including infection and blood-cell abnormalities, and remains a central trade-off when interpreting the reported glucose outcomes.[6]
Is a deceased-donor islet therapy the same as a stem-cell-derived islet therapy?
No. They differ in biological source, preparation, supply constraints and regulatory status. The 2023 US approval of Lantidra concerns deceased-donor pancreatic islets for a narrow patient group.[4] Stem-cell-derived islet products remain investigational.[8] Evidence from one category cannot be used as evidence for the other.
Does clinical-trial registration prove effectiveness?
No. A registry record documents that a study exists and describes its planned methods, status and dates.[9] It does not show that an intervention works, that it is approved, or that it is routinely available. Evidence comes from completed, peer-reviewed human studies measuring defined outcomes in defined populations.[7]
Does submission of a Japanese provision plan mean that a product is approved?
No. A regenerative-medicine provision plan involves review, submission, reporting and patient-information procedures, but submission itself is not product marketing approval or proof of efficacy.[10] Marketing approval of regenerative medical products follows the separate PMD Act product-review pathway, and any approval claim should be checked against the exact product, indication and date in PMDA records.[14]
How can a reader verify whether a product is approved in Japan?
Search the PMDA regenerative medical products pages and the PMDA review-report database for the exact product name.[14][15] Confirm the approved indication, the approval type, and the date, and check whether the status is full, conditional, time-limited or otherwise. A provision-plan record can be checked separately in the published plan database.[11] Neither a clinic page nor promotional material should be treated as proof of regulatory status.
Is Japan Medical a medical provider or referral service?
No. Japan Medical is an independent health-information publisher. It does not provide medical services, referrals, eligibility assessments or medical-record review.
General Enquiry
Would You Like a Source or Term Explained?
Tell Japan Medical which term, claim or public source you would like explained. This is a general information channel, not a medical consultation. Do not send medical records, test results, medical images, identification documents or other sensitive health information.